Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aflibercept for Radiation Maculopathy
NCT02586727Phase 2Completed
- Sponsor
- Larkin Community Hospital
- Start
- Oct 2015
- Primary completion
- Dec 2018
- Modality
- Engineered Antibody Formats, Fc-Fusion Proteins
01
Overview
A Phase 2 trial of aflibercept in Radiation Maculopathy (RM), sponsored by Larkin Community Hospital. Started Oct 2015; status: completed.
02
Drugs
aflibercept
03
Conditions
Radiation Maculopathy (RM)
Beyond the preview
Go deeper on NCT02586727.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02586727.